Holen Sie sich die Stockscreener-App
460.65
1.02%
4.65
Vorhandelsmarkt:
460.65
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Yahoo Finance
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesMarket Performance Recap & Weekly Return Optimization Alerts - newser.com
News impact scoring models applied to Alnylam Pharmaceuticals Inc.July 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Alnylam (ALNY) Begins Phase 3 Trial for Hypertension Drug Zilebe - GuruFocus
Alnylam doses first patient in phase 3 trial of zilebesiran for heart outcomes - MarketScreener
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran - Business Wire
Will Alnylam Pharmaceuticals Inc. (DUL) stock announce special dividendWeekly Trading Summary & Weekly High Potential Stock Alerts - newser.com
U.S. Porphyria Treatment Market Set to Witness Massive Growth - openPR.com
Alnylam Pharmaceuticals Inc Stock Analysis and ForecastStock Buyback Announcements & Individual Stock Tracking Service - earlytimes.in
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growth2025 Breakouts & Breakdowns & AI Forecast for Swing Trade Picks - newser.com
Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - Yahoo Finance
$15B+ Deal Veteran Eric Olson Joins Rare Disease Leader Ultragenyx as Chief Business Officer - Stock Titan
Alnylam Joins Genomic Alliance To Boost RNAi Drug Discovery - Technology Networks
Alnylam Pharmaceuticals, Inc. (ALNY) Reports $492M Amvuttra Sales, Raises 2025 Revenue Guidance - Yahoo
Alnylam and Ionis Pharmaceuticals are the leading companies - openPR.com
Does Alnylam Pharmaceuticals Inc. show high probability of reboundRate Cut & Weekly High Potential Stock Alerts - newser.com
Gene Therapy for Rare Disease Market to Reach US$ 24.54 Bn by 2033, - openPR.com
Wealth Enhancement Advisory Services LLC Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran - Business Wire
Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price actionJuly 2025 Institutional & Verified Trade Idea Suggestions - newser.com
What indicators show strength in Alnylam Pharmaceuticals Inc.July 2025 Recap & Expert Curated Trade Ideas - newser.com
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way? - Yahoo Finance
Will Alnylam Pharmaceuticals Inc. stock sustain high P E ratios2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
What analysts say about Alnylam Pharmaceuticals Inc stockSell Signals and Alerts & Free High Yield Growth Strategies - earlytimes.in
Is Alnylam Pharmaceuticals Inc. stock ready for breakoutRate Hike & AI Driven Stock Reports - newser.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with Strong Buy Ratings and Strategic Collaborations - DirectorsTalk Interviews
Is Alnylam Pharmaceuticals Inc. (DUL) stock a top hedge fund pickMarket Performance Summary & Precise Swing Trade Alerts - newser.com
Vutrisiran treatment reduces GI events in ATTR-CM patients by up to 49% - Investing.com Nigeria
Alnylam (ALNY): Vutrisiran Shows Promise in Reducing Gastrointes - GuruFocus
Alnylam (ALNY): Vutrisiran Shows Promise in Reducing Gastrointestinal Events - GuruFocus
Alnylam says new data from Helios-B Phase 3 study demonstrate lower rates of gastrointestinal events in ATTR-CM patients treated with Vutrisiran - MarketScreener
How Alnylam Pharmaceuticals' (ALNY) Entry to Genomic Data Alliance Could Shape Its Drug Pipeline Progress - simplywall.st
Sowell Financial Services LLC Takes $201,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Benzinga
RNA-Based Therapies Industry Analysis 2025 | Growth, USA Market - openPR.com
8,994 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by ST Germain D J Co. Inc. - MarketBeat
Is Alnylam Pharmaceuticals (ALNY) an Undervalued Stock? - Insider Monkey
Does Alnylam Pharmaceuticals (ALNY) Have the Potential to Generate Strong Long-Term Growth? - Insider Monkey
TB Alternative Assets Ltd. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Cardiac Amyloidosis Pipeline 2025: Pioneering Clinical Developments by 20+ Global Leaders – DelveInsight | Featuring Eidos Therapeutics, Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals - Barchart.com
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bannerman Wealth Management Group LLC Sells 565 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
IFM Investors Pty Ltd Acquires 1,508 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assenagon Asset Management S.A. Purchases 11,281 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Exchange Traded Concepts LLC Sells 909 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Swedbank AB Has $20.97 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00 at Royal Bank Of Canada - MarketBeat
6.70%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):